Pharmaron Beijing (300759) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2026, rose 17.92% year-over-year to ¥7.60 billion, with net profit attributable to shareholders up 6.96% to ¥750 million and adjusted net profit (non-IFRS) up 20.3% to ¥909 million.

• Over 470 new customers were added, with new contract signings growing over 30% year-over-year; revenue from global top 20 pharma clients rose 32% and now accounts for over 20% of total revenue.

• The company maintained solid growth momentum, driven by expansion in strategic customer base, strong performance among large global pharmaceutical companies, and rapid development in new modality projects.

• No interim dividend was declared for the period.

Financial highlights

• Operating cash flow was ¥1.08 billion, down 22.98% year-over-year.

• Gross profit increased 13.9% year-over-year to ¥2.47 billion.

• Basic EPS was ¥0.4138, up 3.87% year-over-year; diluted EPS was ¥0.4113, up 3.4%.

• Total assets at period end were ¥28.95 billion, up 6.84% from year-end; net assets attributable to shareholders were ¥16.35 billion, up 8.53%.

• Gearing ratio was 41.1%, down from 41.9% at year-end 2025.

Outlook and guidance

• Full-year 2026 revenue expected to grow 15–20% year-over-year, driven by robust new contract growth and pipeline advancement.

• Strategic focus on integrated, international, multi-modality R&D service platform, with continued investment in capacity, technology, and global footprint.